simufilam news - Search News

A Controversial Alzheimer’s Drug Has Gone Down in Flames

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent research.

STAT · 2d

Cassava Sciences and its Alzheimer’s drug are done. The damage lingers

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.

The New York Times · 1d

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Reuters on MSN · 2d

Cassava shares sink on plans to stop Alzheimer's drug studies

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.

Becker's Hospital Review · 1d

Controversial Alzheimer's drug trial halted

The trial, which involved patients with mild-to-moderate Alzheimer's disease, failed to show significant improvement in cognition and daily functioning compared to a placebo after 52 weeks, according to a Nov.

Pharmabiz5h

Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints

Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...

Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

pharmaphorum1d

End looms for Cassava's simufilam in Alzheimer's disease

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Zacks.com on MSN1d

SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...

13h

Cassava Sciences: Probably The End Of The Saga

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

thedeepdive1d

Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

STAT1d

Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news

I spent four crazy years writing about Cassava Sciences, Adam Feuerstein writes. Yesterday, the story ended exactly as many ...

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

FierceBiotech2d

Cassava flunks phase 3 Alzheimer's test, triggering early end of 2nd trial and stock crash

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics